Mathieu Anne, Remmelink Myriam, D'Haene Nicky, Penant Stanislas, Gaussin Jean-François, Van Ginckel Rob, Darro Francis, Kiss Robert, Salmon Isabelle
Pathology Laboratory, Erasmus University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Cancer. 2004 Oct 15;101(8):1908-18. doi: 10.1002/cncr.20571.
Nonsmall cell lung carcinomas (NSCLCs) are associated with very dismal prognoses, and adjuvant chemotherapy, including irinotecan, taxanes, platin, and vinca alkaloid derivatives, offer patients only slight clinical benefits. Part of the chemoresistance of NSCLC results from the expression in NSCLC cells of a very large set of endogenous proteins, which antagonize chemotherapy-mediated attacks on these tumor cells.
The authors set up an orthotopic model of a human NSCLC by grafting A549 cells into the lungs of nude mice. They tried treating these A549 NSCLC orthotopic xenograft-bearing nude mice on the basis of various chemotherapeutic protocols, including chronic administrations of taxol, oxaliplatin, and irinotecan. A cyclooxygenase-2 (COX-2) inhibitor (NS-398) also was assayed in combination with taxol. The immunohistochemical expression levels of COX-2, prostaglandin E synthetase (PGES), ornithine decarboxylase (ODC), the lung-related resistance protein (LRP), and glutathione-S-transferase-alpha (GST-alpha), GST-mu, and GST-pi were quantitatively determined by means of computer-assisted microscopy in control and drug-treated NSCLC orthotopic xenografts.
The orthotopic A549 xenograft model developed in 100% of the grafted mice, leading to brain metastases in approximately 61% mice and to liver metastases in approximately 40% of mice. The model was resistant to taxol and oxaliplatin and was only weakly sensitive to irinotecan. High levels of chemoresistant markers (i.e., COX-2, PGES, ODC, LRP, GST-alpha, GST-mu, and GST-pi) were observed in the nontreated A549 xenografts, although with dramatic variations in individual expression. Taxol and oxaliplatin significantly increased the levels of expression of COX-2, PGES, GST-mu, and GST-pi in a number of different experimental protocols.
The A549 orthotopic xenograft model could be used to evaluate investigational chemotherapeutic agents to identify drugs rapidly that are more active than the drugs currently in use in hospitals.
非小细胞肺癌(NSCLC)的预后非常糟糕,包括伊立替康、紫杉烷、铂类和长春花生物碱衍生物在内的辅助化疗仅能给患者带来轻微的临床益处。NSCLC的部分化疗耐药性源于NSCLC细胞中大量内源性蛋白质的表达,这些蛋白质可拮抗化疗对这些肿瘤细胞的攻击。
作者通过将A549细胞移植到裸鼠肺部建立了人NSCLC原位模型。他们尝试根据各种化疗方案治疗这些携带A549 NSCLC原位异种移植瘤的裸鼠,包括长期给予紫杉醇、奥沙利铂和伊立替康。还将环氧化酶-2(COX-2)抑制剂(NS-398)与紫杉醇联合进行了检测。通过计算机辅助显微镜定量测定了对照和药物治疗的NSCLC原位异种移植瘤中COX-2、前列腺素E合成酶(PGES)、鸟氨酸脱羧酶(ODC)、肺相关耐药蛋白(LRP)以及谷胱甘肽-S-转移酶-α(GST-α)、GST-μ和GST-π的免疫组化表达水平。
100%的移植小鼠成功建立了A549原位异种移植模型,约61%的小鼠发生脑转移,约40%的小鼠发生肝转移。该模型对紫杉醇和奥沙利铂耐药,对伊立替康仅轻度敏感。在未治疗的A549异种移植瘤中观察到高水平的化疗耐药标志物(即COX-2、PGES、ODC、LRP、GST-α、GST-μ和GST-π),尽管个体表达存在显著差异。在许多不同的实验方案中,紫杉醇和奥沙利铂显著提高了COX-2、PGES、GST-μ和GST-π的表达水平。
A549原位异种移植模型可用于评估研究性化疗药物,以快速识别比医院目前使用的药物更有效的药物。